Clinical Trials Sponsored by Janssen-Cilag Farmaceutica, S.R.L.

Total 20 results

Centocor, Inc.
Janssen-Cilag Farmaceutica, S.R.L.

Completed

A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma

Melanoma

United States, United Kingdom, Germany
Janssen-Cilag Farmaceutica Ltda.

Completed

A Study to Evaluate Virologic Response in Participants Newly Diagnosed With HIV-1

HIV

Portugal
Janssen-Cilag Farmaceutica Ltda.

Completed

The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life

Dementia
Janssen-Cilag Farmaceutica Ltda.

Completed

Study to Evaluate the Efficacy and Quality of Life of Long-Acting Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Brazil
Janssen-Cilag Farmaceutica Ltda.

Completed

A Study of Pharmacodynamic and Genetic Parameters of Abira-DES Study Participants (NCT02217566) - Participants With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Following Unresponsive Treatment With Diethylstilbestrol (EXPLORE)

Metastatic Castration-resistant Prostate Cancer

Brazil
Janssen-Cilag Farmaceutica Ltda.

Completed

Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate

Schizophrenia

Colombia, Mexico, Brazil
Janssen-Cilag Farmaceutica Ltda.

Completed

A Study to Evaluate Participants Satisfaction, Quality of Life and Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in Participants With Schizophrenia, Previously Treated With Risperidone

Schizophrenia

Brazil
Janssen-Cilag Farmaceutica Ltda.

Completed

A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal (PsiProsper)

Schizophrenia

Portugal
Janssen-Cilag Farmaceutica Ltda.

Approved for marketing

Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

B-cell Chronic Lymphocytic Leukemia

Brazil
Janssen-Cilag Farmaceutica Ltda.

Completed

An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of Norelgestromine and Ethinyl Estradiol

Contraception

Brazil, Mexico
Janssen-Cilag Farmaceutica Ltda.

Completed

An Efficacy and Tolerability Study for Topiramate in Obese Patients With Binge Eating Disorder.

Binge Eating
Janssen Cilag Pharmaceutica S.A.C.I., Greece

Completed

Study of the Safety and Effectiveness of Rabeprazole in Treatment of Helicobacter Pylori Infection in Adults.

Bacterial Infections | Helicobacter Infections
Janssen Cilag Pharmaceutica S.A.C.I., Greece

Completed

A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux | Heartburn
Janssen Cilag Pharmaceutica S.A.C.I., Greece

Completed

An Observational Study of the Safety of Topiramate in Adults and Children With Epilepsy

Seizures, Epileptic
Janssen Cilag Pharmaceutica S.A.C.I., Greece

Completed

A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease

Alzheimer Disease
Janssen Cilag Pharmaceutica S.A.C.I., Greece

Completed

A Study of the Safety of Topiramate Given in Combination With Other Medications in Adults and Children With Seizures

Epilepsy | Seizures
Janssen Cilag Pharmaceutica S.A.C.I., Greece

Completed

An Observational Study Evaluating the Safety of Topiramate for the Prevention of Migraine

Migraine Disorders
Janssen-Cilag Farmaceutica Ltda.
Janssen Korea, Ltd., Korea

No longer available

An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

Hong Kong, Brazil, Thailand
University Hospital, Clermont-Ferrand
Janssen-Cilag Farmaceutica Ltda.

Completed

Alzheimer and Sleep

Alzheimer's Disease

France
Fondazione Italiana Linfomi ONLUS
Janssen Pharmaceutica; Janssen-Cilag Ltd.; Centro di Riferimento per l'Epidemiologia...

Completed

Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. (FIL_VERAL12)

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B-cell Lymphoma Refractory

Italy

3

Subscribe